Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14926 - 14950 of 15363 in total
MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.
Investigational
Matched Description: … orally administered drug candidate under development by Merck for the treatment of atherosclerosis and
Avasopasem manganese, also known as GC4419, is a highly-selective small molecule mimetic of superoxide dismutase (SOD) being investigated for the reduction of radiation-induced severe oral mucositis.[L27246, L27256] This drug has potential application for radiation-induced esophagitis and oral mucositis, in addition to being currently tested against COVID-19.
Investigational
Matched Description: … [L27246, L27256] This drug has potential application for radiation-induced esophagitis and oral mucositis …
VSF-173 is an oral small molecule. It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect. It is developed for the treatment of excessive sleepiness. Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive...
Investigational
Matched Description: … It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression …
PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).
Investigational
Matched Iupac: … N-[(1S)-1-(3-fluorophenyl)-3-[(1R,3S,5S)-3-[2-methyl-5-(2-methylpropanoyl)-1H,4H,5H,6H,7H-imidazo[4,5 …
Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.
Investigational
β-Hydroxythiofentanyl is an analgesic of the opioid class. This drug is an analog of fentanyl, a potent opioid.
Illicit
CHF 4227 is a new selective estrogen receptor modulator (SERM). The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used...
Investigational
Matched Description: … The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone …
Exicorilant is under investigation in clinical trial NCT03437941 (Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With Mcrpc).
Investigational
Matched Iupac: … 2-[(4aR,8aS)-1-(4-fluorophenyl)-6-[(2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl]-1H,4H,4aH,5H,6H,7H,8H,8aH …
Experimental
Experimental
Matched Iupac: … amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)methyl
Investigational
Matched Iupac: … hydroxymethyl)oxolan-2-yl]oxy}-6-({[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl
An anticholesteremic agent.
Experimental
A muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide.
Withdrawn
Displaying drugs 14926 - 14950 of 15363 in total